Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Nerviano Medical inks protein kinase collaboration with Servier
September 2013
SHARING OPTIONS:

NERVIANO, Italy—Nerviano Medical Sciences and Servier have signed a worldwide license agreement to develop and commercialize first-in-class compounds from Nerviano that inhibit the protein kinase TTK/MPS1, a key regulator of mitosis that is over-expressed in a variety of tumors. Per the terms of the agreement, Nerviano will complete preclinical development for the lead candidate drug, and if Servier exercises its option, the latter will be responsible for all development and commercialization costs, with Nerviano continuing to support Servier for early clinical development and supply of the licensed product. The collaboration includes an upfront payment of $10.6 million, with the potential for up to $133.4 million in option fees, clinical and regulatory milestones and royalties on sales of licensed products.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.